Buying SS-31 in the USA: Why It Concentrates Where It Does

A research peptide is usually defined by the receptor it binds. SS-31, also known as elamipretide, is not. It belongs to a small family of tetrapeptides whose defining property is a destination rather than a target: what characterizes the family is where in the cell the molecule ends up.

The lipid it associates with

Cardiolipin is a dimeric phospholipid. Two phosphatidyl units are joined through a glycerol bridge, so four acyl chains sit beneath a single small head group. That geometry is conical, and conical lipids favor negative membrane curvature, which is why tightly folded cristae depend on it. The lipid is found essentially nowhere except the inner mitochondrial membrane, and it is particularly enriched at the cristae membrane. SS-31 associates with this lipid rather than with any protein receptor.

Two of cardiolipin’s structural roles bear directly on the compound.

• Supercomplex organization. Complexes I, III and IV assemble into higher-order supercomplexes, with cardiolipin occupying the interfaces between them. Deplete, oxidize or abnormally remodel the cardiolipin and those assemblies destabilize, electron transfer loses efficiency, and leak to oxygen rises, producing more reactive oxygen species from an unchanged substrate load.
• Cytochrome c tethering. Cardiolipin helps hold cytochrome c at the membrane. In complex with cardiolipin, cytochrome c takes on peroxidase activity and oxidizes the very lipid it is bound to; the peroxidized cardiolipin then releases cytochrome c into the intermembrane space, a proximal event in intrinsic apoptosis.

Why lipid targeting is the whole argument

The SS family shares an alternating aromatic-cationic sequence. At physiological pH that arrangement gives the molecule a net positive charge while also presenting aromatic residues, and together those features drive accumulation in the inner mitochondrial membrane. Published descriptions put particular weight on one point: uptake is largely independent of membrane potential. That is what separates the SS peptides from the earlier generation of cationic mitochondrial probes, whose accumulation collapses as soon as the membrane depolarizes.

Conventional mitochondrial targeting chemistry runs on the membrane potential. Triphenylphosphonium conjugates and comparable lipophilic cations accumulate in the matrix because the inner membrane is negative on the inside; the driving force is purely electrical. For anyone studying dysfunctional mitochondria that has an obvious defect, since depolarization reduces accumulation and the compound therefore concentrates least in precisely the organelles where the pathology lies.

The SS peptides are instead described as associating with the membrane through the cardiolipin interaction rather than being driven electrophoretically into the matrix. Taken at face value, that description means the compound reaches a depolarized mitochondrion as readily as a healthy one. It is the mechanistic case for the family, and it is a reason to state the distinction carefully rather than filing SS-31 alongside cationic probes generally.

The premise is also testable. If the mechanism is as described, a depolarizing agent such as FCCP should leave SS-31 localization intact while abolishing that of a TPP-conjugated comparator. Running the pair turns the premise into a result.

Upstream of reactive oxygen species, or downstream of them

What the literature proposes is that binding stabilizes cardiolipin-dependent supercomplex organization and suppresses the acquired peroxidase activity described above. Both consequences are structural rather than signaling, which is why SS-31 is usually called a membrane-interacting agent instead of an agonist. It also implies that the compound would act upstream of reactive oxygen species formation rather than scavenging species already produced, and that is a distinction a well-built experiment ought to be trying to resolve. The primary literature is indexed at PubMed, with a separate index for elamipretide.

Designing an experiment with no receptor to assay

No receptor means no binding assay, no Ki, no selectivity ratio and no structure-activity series in the conventional sense. Everything therefore rests on functional readouts and on the controls placed around them.

• Respirometry. Extracellular flux or high-resolution respirometry giving basal, ATP-linked, leak, maximal and spare capacity. Cell number per well shifts these figures substantially, so seeding density must be normalized and reported.
• Membrane potential. TMRM in non-quench mode or JC-1, always with a depolarizing control alongside. Loading differences confound both dyes.
• Reactive oxygen species. MitoSOX or a compartment-targeted redox sensor. The MitoSOX signal is itself potential-dependent, which is a genuine trap whenever the intervention also shifts potential, and a well-documented artifact in exactly this literature.
• Supercomplex assembly. Blue-native PAGE with in-gel activity staining, or complexome profiling. This readout sits closest to the proposed mechanism of any on the list, and it is the one most often omitted.
• Cristae ultrastructure. Transmission electron microscopy, or super-resolution imaging where sample numbers are larger.
• Cardiolipin peroxidation measured directly by lipidomics when the question justifies the effort.

Controls this compound specifically requires

• A conventional antioxidant comparator, to separate a mechanism-specific effect from general redox buffering. If a plain scavenger reproduces the result, the cardiolipin argument is not doing the explaining.
• A potential-dependent mitochondrial agent such as a TPP conjugate, so that the potential-independence claim is tested rather than cited.
• A scrambled or non-targeting peptide matched for charge, since a cationic peptide produces membrane effects that owe nothing to its sequence.
• Normalization to mitochondrial content through citrate synthase activity or mtDNA copy number, so that a change in respiration is not merely a change in how many mitochondria are present.

Concentration is not transferable between papers

Membrane-interacting compounds often show non-monotonic concentration-response relationships. An effect appears in the low nanomolar range, plateaus, then reverses or disappears at higher concentrations as the compound begins perturbing the membrane it was stabilizing. Lifting a single concentration out of someone else’s paper is consequently a poor bet, and it is among the more common causes of failed replication in this area.

The remedy is unglamorous. Run the full concentration range in your own system before fixing a working concentration, and publish the entire curve instead of the one point that behaved.

Adsorption and apparent potency

This deserves more than a footnote, because it is the single likeliest explanation for potency disagreements between laboratories. SS-31 is short and strongly cationic, and at nanomolar working concentrations a meaningful fraction adheres to glass and to untreated polypropylene. Nothing has degraded; the compound is simply no longer in solution.

• Low-binding tubes and tips through the whole dilution series, not just the final step.
• Carrier protein in dilution buffers wherever the assay tolerates it.
• Fresh working dilutions in place of stored dilute solutions, since that is where the surface-to-volume ratio is worst.
• Matched labware across arms. Different plasticware for vehicle and compound confounds the comparison before any measurement is taken.

What the analytical record should show

• Mass against the stated sequence. A tetrapeptide has an unambiguous target mass, which makes this a strong check. Whether the C-terminus is amidated should be confirmed as well.
• Stereochemistry. The sequence contains a D-residue, and D and L epimers are isobaric, so mass spectrometry cannot separate them. Chiral analysis or a stated synthetic route is what establishes this, and a certificate seldom carries either.
• RP-HPLC purity with gradient, column and wavelength on the record. The aromatic residues absorb strongly at 280 nm, so a 280-only trace under-reports non-aromatic impurities; 214 nm gives the fuller picture.
• Net peptide content. Proportionally large here, because counterion mass does not scale down with chain length the way peptide mass does. See net peptide content explained.
• Counterion identity. Residual trifluoroacetate is active in some cell assays, and mitochondrial viability readouts are among the more sensitive to it. See counterions and salt form.

Handling in the laboratory

The material is supplied lyophilized. As with other short cationic peptides, surface adsorption at low concentrations is a real practical issue and can show up as an apparent potency difference between laboratories for no reason other than differing labware. Reconstitution and storage guidance is in our storage and stability note. Product page: SS-31 10mg.

A neighboring compound that is not the same thing

MOTS-c is often studied next to SS-31 but shares no mechanism with it. It is a mitochondrial-derived peptide encoded in the mitochondrial genome, and it acts largely through nuclear signaling rather than membrane association. Grouping the two under one heading conceals that difference. Both, along with NAD-related compounds, are listed under mitochondrial and cellular compounds, and the distinction is developed further in our note on MOTS-c and SS-31.

Glossary

• Cardiolipin — dimeric phospholipid of the inner mitochondrial membrane; supports cristae curvature and supercomplex assembly.
• Cristae — inner-membrane folds housing the electron transport chain.
• Supercomplex — higher-order assembly of respiratory complexes.
• Membrane potential — charge gradient across the inner membrane; drives ATP synthesis and most mitochondrial targeting chemistry.
• TPP conjugate — triphenylphosphonium-tagged molecule that accumulates by electrical driving force.
• Non-monotonic dose response — an effect that does not rise steadily with concentration.
• Proton leak — oxygen consumption uncoupled from ATP synthesis.

ExoLabz supplies compounds for laboratory research use only. Nothing on this page is medical advice or a suggestion of human or veterinary use.